Cystic fibrosis (CF) is a genetic condition that causes the body to produce abnormally thick, sticky mucus. In babies, this mucus builds up in the lungs, digestive tract, and other organs, interfering with breathing and the ability to absorb nutrients from food. Every state in the U.S. screens for CF at birth, so most babies are diagnosed within the first few weeks of life, often before symptoms appear.
How Cystic Fibrosis Works
The body has a protein that controls how salt and water move in and out of cells. In babies with CF, a faulty version of this protein disrupts that balance. Cells end up with too little water on their surfaces, which makes the mucus lining the lungs, pancreas, and intestines far thicker than normal. That same protein defect also increases the amount of salt in sweat, sometimes to two to five times the normal level.
CF is inherited. A child must receive one copy of the faulty gene from each parent to develop the condition. When both parents are carriers (meaning they each have one faulty copy but no symptoms themselves), each pregnancy carries a 25% chance the baby will have CF, a 50% chance the baby will be a carrier without the disease, and a 25% chance the baby won’t carry the gene at all.
How Babies Are Diagnosed
Newborn screening catches most cases. A few drops of blood are collected from the baby’s heel shortly after birth, and a lab measures a substance called immunoreactive trypsinogen (IRT). Elevated IRT doesn’t confirm CF on its own. In most states, a second test on the same blood sample checks for changes in the gene responsible for the disease. If both results are concerning, the baby is referred for a sweat test.
The sweat test measures how much chloride (salt) is in the baby’s sweat. It’s the gold standard for confirming CF. A small area of skin, usually on the forearm, is stimulated to produce sweat, which is then collected and analyzed. The test is painless and takes about 30 minutes. High chloride levels confirm the diagnosis.
Early Signs Parents May Notice
One of the most commonly reported early signs is salty-tasting skin. Parents often notice it when kissing their baby’s forehead or cheeks. This observation has been recognized for centuries. Long before CF was formally identified, physicians knew that a salty brow in an infant signaled serious illness.
Between 10% and 20% of babies with CF develop a bowel blockage called meconium ileus at birth. Meconium is the dark, tar-like first stool every newborn passes. In babies with CF, the meconium can be so abnormally thick that it plugs the lower portion of the small intestine, causing abdominal swelling and preventing normal bowel movements. This sometimes requires surgical intervention and may be the very first clue that a baby has the condition.
Other early signs include persistent coughing or wheezing, frequent lung infections, poor weight gain despite a good appetite, and greasy or foul-smelling stools. Some babies seem to eat well but still fail to grow as expected, a red flag that their pancreas isn’t releasing enough digestive enzymes.
Digestive Challenges and Nutrition
The thick mucus characteristic of CF blocks the ducts of the pancreas, preventing digestive enzymes from reaching the intestines. Without these enzymes, a baby’s body can’t properly break down fats and proteins from breast milk or formula. Left untreated, this leads to weight loss, abdominal bloating, diarrhea, and bulky, oily stools.
Most babies with CF need enzyme supplements given with every feeding. For infants, caregivers open enzyme capsules and mix the tiny beads with a small amount of applesauce or another slightly acidic food. The beads should not be crushed or left sitting in food, since moisture and alkaline environments break down the enzymes before they can work. Getting the timing and dose right is one of the first practical skills parents learn after diagnosis.
Calorie needs are significantly higher than for other children. Toddlers with CF typically require 30% to 50% more calories than their peers. While most toddlers need about 1,000 to 1,300 calories daily, a toddler with CF may need 1,300 to 1,900 calories. This higher caloric demand begins in infancy, and CF care teams work closely with families on strategies to boost calorie intake through fortified breast milk, higher-calorie formulas, or added fats.
Lung Care From the Start
Even before a baby shows respiratory symptoms, mucus is already building up in the airways. Airway clearance therapy begins early, often within the first weeks after diagnosis. For infants, this centers on a technique called chest physical therapy (CPT). A caregiver positions the baby across their lap, sometimes using small pillows, so gravity helps drain different sections of the lungs. The caregiver then gently claps on the baby’s chest wall with a cupped hand, creating a cushion of air that softens the impact while loosening mucus from the airway walls. Each position is held for about three to five minutes, sometimes followed by gentle vibration over the same area.
This routine is typically done one to four times per day, depending on the baby’s needs, and becomes a normal part of daily life for CF families. As children grow, they can transition to other airway clearance methods, but in infancy, hands-on percussion by a parent or caregiver is the primary approach.
Treatments Available for Infants
A major advance in CF treatment has been the development of medications that fix the underlying protein defect rather than just managing symptoms. The FDA has approved ivacaftor (sold as Kalydeco) for babies as young as 6 months old who have certain genetic mutations. In a 24-week study of 11 infants between 6 and 12 months, the medication was well tolerated with no new safety concerns. For eligible babies, starting this type of therapy early may help preserve lung function and improve digestion before significant damage occurs.
Not all babies qualify for these newer therapies. Eligibility depends on which specific gene mutations the baby carries. A CF care team will review genetic testing results to determine the best treatment plan, which for most infants includes a combination of enzyme supplements, airway clearance therapy, and close nutritional monitoring.
What the Outlook Looks Like Today
The prognosis for babies born with CF has improved dramatically. According to the Cystic Fibrosis Foundation’s 2024 Patient Registry data, half of children born with CF between 2020 and 2024 are predicted to live to age 65 or beyond. That figure was unimaginable a generation ago, when CF was often fatal in childhood. The improvement reflects decades of progress in newborn screening, daily treatment routines, nutritional support, and newer medications that target the root cause of the disease rather than its symptoms.
CF still requires daily, lifelong management. But babies diagnosed today enter a care landscape that is vastly different from what existed even 10 years ago, with specialized CF centers, structured treatment protocols, and therapies that can begin in the first months of life.